PTU-121 'CHOLECYSTECTOMY' IS IT BEST SERVED HOT?

Kristof Nemeth*, Rob Quinn, Anil Kaul. *Whiston Hospital, Prescot, UK*

10.1136/gutjnl-2018-BSGAbstracts.499

Introduction The traditional approach to the management of gallstone-related diseases and their acute exacerbations has been conservative for decades.

The long standing paradigm of endoscopic extraction of obstructing gallstones with interval cholecystectomy at the end of a cool-down period of 4 to 6 weeks has been challenged in recent years.

The National Institute for Health and Care Excellence (NICE, 2014) is recommending that patients with acute cholecystitis should have a laparoscopic cholecystectomy (LC) within a week of admission and the International Association of Pancreatologists (IAP, 2013) recommends patients with gallstone pancreatitis to have LC on index admission.

Methods At our hospital we have established a 'hot gallbladder' service in addition to our emergency operating list with once a week dedicated sessions for patients presenting with symptomatic gallstones.

A prospective database of all 'hot' patients is maintained and we have carried out a safety and feasibility study of our 2017 cohort of patients.

Results In 2017 409 cases with a median age of 58 year (range: 15 to 97) were referred to our department with hard evidence of gall stone disease.

In terms of 'hot gallbladder' cases, 117/409 were deemed suitable for the hot gallbladder list, but 19/117 patients declined surgery.

Out of the 98/117 patients 60/98 same admission LCs were performed with good results.

The median age of patients was 45 years (range: 20 to 97). The Male: Female Ratio was 1:2.5

54/60 cases were completed laparoscopically, 4/60 required conversion and 1/60 case was abandoned with a cholecystectomy *in-situ*. The number of subtotal cholecystectomies was 5/60.

We had no 30 day mortality and there were no biliary tract injuries.

In terms of surgical complications there was 1/60 post-operative haematoma, 1/60 bile leak and 1/60 intraoperative spillage of gall stones. 3/60 patients required readmission.

The length of stay (LOS) for the 'hot gallbladder' cohort was median 6 days (range: 0 to 17). The median length of time between onset of symptoms and presentation to hospital was 1 day (range: 0 to 21 days) and obtaining ultrasound scans took median 1 day (range: 0 to 3). The median waiting time for magnetic resonance cholangiopancreatography (MRCP) was 3 days from admission (range: 1 to 7).

In contrast the median LOS for all gall-stone related admissions in the same period were 6 days with range 0 to 56 days.

Conclusion Our experience of managing gallstone disease with prompt cholecystectomy during the same admission shows that this approach provides safe and cost-effective patient care.

In order to improve efficiency we are actively working on establishing further 'hot gall bladder' lists during the working week and reduction of waiting times for imaging is desirable.

PTU-122 ACUTE UPPER GASTROINTESTINAL BLEEDING MANAGEMENT: A MULTI-CENTRE, TRAINEE LED AUDIT IN NORTH-WEST ENGLAND

Kirsty Nixon*, Katherine White, GasTRINNoW Collaborators. *Gastroenterology Trainee Research and Improvement Network North West, Manchester*

10.1136/gutjnl-2018-BSGAbstracts.500

Background Despite advances in diagnostics and therapy, acute upper gastrointestinal bleeding (AUGIB) is associated with 10% mortality. The National Institute for Health and Care Excellence clinical guideline (NICE) key priorities for implementation. Using the newly formed Gastroenterology Trainee Research and Improvement Network North West (GasTRIN NoW), we aimed to obtain multi-centre data to audit the management of AUGIB.

Method A prospective multi-centre AUGIB audit was undertaken across 10 hospitals in North West England between 30/10/2017-26/11/2017. 11 patients admitted with suspected UGIB who underwent endoscopy (OGD). Standards were 0% 100% be offered OGD within 24 hours of admission. Each centre registered the audit locally and anonymised data was pooled within excel for further analysis in R.

Results patients were included across 10 hospitals 83% (n=101) were referred from A+E 17% via primary care. Median age was 65 years (IQR 50-77) 66% were male. 50% (n=60) were admitted during weekdays between 07:00 and 19:00. At admission, 46% (n=56) had either a Glasgow Blatchford or pre-ockall score. 32 patients were on anti-platelet, 21 on anticoagulants (warfarin, DOAC or LMWH) and 16 on NSAIDs (13%), 64% (n=70) received either oral or IV PPI prior to OGD.

Fiftyfour percent of those with varices required banding or glue therapy (n=7/13) while 12% (n=13/108) required therapy for non-variceal bleeding. Haemostasis was achieved in 90% (n=18). Length of stay in these patients were longer compared to those not requiring therapy (median 6 days (IQR: 5-7) vs. 4 days (IQR: 2-7); p=0.04). There were 7 deaths at 30 day follow up only 1 directly attributable to AUGIB.

Conclusion NICE standards comparable to data presented by The GARnet Improvements are needed to deliver NICE standards

PTU-123 EFFECTIVENESS OF A DIETETIC-LED IBS SERVICE IN THE MANAGEMENT OF PATIENTS OVER 45 YEARS

Claire Oldale*, Natasha Cook, Alexandra Di Mambro. *Glos Hospitals NHS Foundation Trust, Cheltenham, UK*

10.1136/gutjnl-2018-BSGAbstracts.501

Introduction The low FODMAP diet is known to be effective in improving symptoms in approx. 70% of those with Rome criteria IBS. Whilst the majority of IBS patients are young adults, there is a cohort of patients over the age of 45 with IBS who may benefit from similar interventions. In January 2017, the dietetic-led refractory IBS (RIBS) Service in Gloucestershire expanded its direct access inclusion criteria to allow GP referral of patients >45 years with negative GI investigation within the previous 5 years and no change in symptoms. Consultant referrals following negative investigation in this age group are also accepted.

Methods This is a retrospective analysis of data collected during patient consultations. Patients over 45 years referred to the RIBS service by GP or consultant were assessed and provided with detailed advice on a low FODMAP diet by a specialist dietitian, to be followed for 6 weeks. An 11 point symptom evaluation was completed before and after dietary manipulation and total scores were calculated. Typical bowel frequency and stool consistency were recorded, along with responses to a global symptom question 'do you currently have satisfactory relief of your gut symptoms?'

Results 107 patients >45 years of age have completed treatment within the RIBS service (82% with diarrhoea or mixed symptom predominance). Individual and total symptom scores demonstrate an average reduction in severity of almost 50% after following a FODMAP exclusion diet (figure 1), with mean total symptom score before treatment 60.9 (range 27–89/110) reducing to 36.0 after treatment (range 11–89/110). Sixty-seven percent (72/107) of patients reported satisfactory relief of their gut symptoms following dietary restriction (figure 2). Direct-access patients who did not respond to treatment were discussed within a consultant-led MDT, with further advice, clinician review or investigation arranged as appropriate. No known cases of IBD or cancer have been missed to date using this pathway of care.

Abstract PTU-123 Figure 1 Pre (appt 1) and post (appt 2) treatment symptom scores

Abstract PTU-123 Figure 2 Do you currently have satisfactory relief of your gut symptoms?

Conclusions Treatment within a dietetic-led, direct-access service with an appropriate, policed care pathway and MDT support is a safe and clinically effective management strategy for patients over the age of 45 with diagnosed IBS symptoms.

The pathway provides an important adjunct to 'straight to test' referral protocols for GP's in those over 45 with stable symptoms and previously negative colonoscopy, diverting these patients from unnecessary specialist review and costly further investigation.

PTU-124

REAL WORLD TOLERABILITY & EFFICACY OF ORAL FERRIC MALTOL (FERACCRU) IN IBD ASSOCIATED ANAEMIA

¹Philip Oppong*, ²Silvia Lovato, ¹Ayesha Akbar. *St Mark's Hospital, Harrow, UK* ²Ealing Hospital, UK

10.1136/gutjnl-2018-BSGAbstracts.502

Introduction Anaemia is common in inflammatory bowel disease (IBD). Quality of life can be improved with anaemia correction.¹ Conventional oral iron therapies are poorly tolerated in IBD patients.² European Crohn's and Colitis Organisation (ECCO) guidelines suggest intravenous (IV) replacement in patients with previous intolerance to oral iron.³

Feraccru, a new oral iron complex, is cheaper than IV iron and does not require administration in hospital. In a phase 3 randomised placebo controlled trial it improved mean haemoglobin (Hb) by 2.25 g/dL at week 12 in patients whom previous oral ferrous products had failed. We assessed the tolerability and efficacy of Feraccru in the real world.

Methods Patients over 18 with IBD who were prescribed Feraccru between 1 February and 31 October 2017 at the London Northwest Healthcare NHS Trust were identified prospectively from prescribing clinicians and dispensary records. Data was collected from medical records and patients were contacted at least 1 month after prescription of Feraccru to assess tolerability.

Results 28 patients (16 ulcerative colitis, 12 Crohn's) were prescribed Feraccru during the study. 17/28 had taken other oral iron supplements in the past 2 years of whom 12/17 had adverse effects, the commonest being abdominal pain.

14/21 patients tolerated Feraccru (7 not contactable). 3/14 that tolerated Feraccru stopped it early due to ongoing IBD symptoms. Of the 7/21 that did not tolerate it, no serious adverse events were noted; the most common side effect was abdominal pain. 5/10 patients who did not tolerate conventional oral iron tolerated Feraccru (2 not contactable).

Median baseline Hb was 110 g/dL (IQR 105–127) and ferritin 14mcg/L (IQR 12–21). 20/28 had post Feraccru bloods with a median of 114 days (IQR 92–144) between blood tests. Median post Feraccru Hb was 122 g/dL (IQR 116–134) and ferritin 28mcg/L (IQR 13–43). Hb incremented in 16/20; median increment 14 g/dL (IQR 8–19). Hb fell in 4/20; median fall 17.5 g/dL (IQR 7.8–27.3). 6/22 had IV iron up to 4 months after their last Feraccru dose.

Conclusions Feraccru was prescribed for IBD patients with mild iron deficiency anaemia. It was tolerated in 67% of all patients and in 50% of patients who were intolerant of conventional oral iron preparations. Hb incremented in most. Feraccru may be considered as a safe and cost effective alternative to IV iron in patients with mild IDA. Larger real life patient cohorts need to be studied, and disease activity should also be a consideration.

REFERENCES

1. Wells CW, et al. *Inflamm Bowel Dis* 2006;**12**:123–30.
2. Lugg S, et al. *J Crohn's Colitis*. 2014;**8**:876–880.